Table 4 Organisations and individuals noted by respondents as having an important influence on changing policies related to the use of magnesium sulphate in their countries (%)
Organisation or individuals | Low and lower-middle income countries (n = 39#) | Upper-middle income countries (n = 20#) | High-income countries (n = 24#) |
|---|---|---|---|
Medical or obstetrical association | 92% | 85% | 88% |
Hospital department of obstetrics | 87% | 85% | 83% |
Central health authorities | 82% | 70% | 38% |
Hospital administration | 79% | 60% | 17% |
World Health Organisation | 79% | 45% | 8% |
Nurse or midwife association | 72% | 35% | 58% |
Drug licensing agency | 72% | 10% | 46% |
Pharmaceutical industry | 69% | 25% | 33% |
Regional or local health authorities | 67% | 90% | 33% |
Mass media | 56% | 20% | 46% |
Individual influential professionals | 51% | 55% | 75% |
Politicians | 51% | 55% | 8% |
Public health insurance program | 26% | 65% | 13% |
Private health insurers | 26% | 35% | 8% |
Non-governmental organisations | 26% | 15% | 4% |
Other international organisations | 26% | 15% | 4% |
Other professional associations | 21% | 15% | 17% |
Patient organisations | 13% | 10% | 33% |
Others | 13% | 25% | 21% |